Respiratory drug delivery is specially used to treat the diseases of lung and nose. This type of drug delivery offers complete non-invasive or painless approach to the topical active medications or the systemic drugs. Lung and the nose are mostly the targeted organs of the delivery of drugs that offer the opportunity for aerosol delivery of drug. This is majorly done through deposition on the right surface. Nonetheless, clearance ad filter mechanisms of the candidate’s body must be overcome for achieving successful applications. The much required size of particles majorly stimulates the technological methods for the production of aerosol through different inhalers. These include the nebulizers, pressurized metered dose inhalers, dry powder inhalers, and the non-pressurized liquid inhalers.
Respiratory Drug Delivery Market accounted for over US$ 39 billion in 2019. It is anticipated to grow at a CAGR of approximately 6.8% from 2020 to 2030.
Respiratory drug delivery offers treatment for diseases of the respiratory tract through noninvasive means to deliver either topically active medications or systemic drugs to target organs. The nose and lung are the target organs for the deposition of the aerosol drug. In asthma, drug delivery to the upper airways is needed while for alveolar lung diseases, such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis, it is important to have drug deposition deep within the lungs rather than just the upper airways.
Major Key Players of the Respiratory Drug Delivery Market are:
3M, GlaxoSmithKline plc., AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH., Philips Respironics, Merck & Co., Inc., OMRON Healthcare, Cipla Inc., and others.
No comments:
Post a Comment